TAR-200, a novel bladder implant delivering gemcitabine, shows striking results for high-risk, non-muscle-invasive bladder cancer that failed prior treatments. The pretzel-shaped device is inserted via catheter and slowly releases chemotherapy over three weeks, allowing prolonged contact with tumors compared with standard liquid therapy.
In the phase 2 SunRISe-1 trial, 82% of 85 patients achieved complete tumor elimination, often within three months, and nearly half remained cancer-free at one year. These patients had disease unresponsive to BCG immunotherapy, leaving surgery as the usual last resort.
The treatment was well tolerated, with few serious side effects. The FDA has granted Priority Review for TAR-200, highlighting its potential to address an unmet need. If approved, TAR-200 could offer a less invasive, highly effective alternative to radical cystectomy, potentially transforming care for patients with treatment-resistant bladder cancer.